康宁杰瑞制药-B(09966)发布公告，于2025年10月16日，该公司斥资548.3万港元回购40万股。 ...

格隆汇10月16日丨康宁杰瑞制药-B(09966.HK)公告，10月16日耗资548.3万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年10月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | ...

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

Summary of Key Points Core Viewpoint - A number of companies, including Xiaomi Group and Kuaishou, conducted share buybacks on October 14, 2025, with Xiaomi leading in terms of buyback amount and quantity [1]. Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 195 million, with a year-to-date total of 10.5954 million shares, representing 0.040% of its total share capital [2]. - Kuaishou-W (01024) repurchased 1.3146 million shares for 98.4067 million, with a year-to-date total of 3.4516 million shares, representing 0.081% of its total share capital [2]. - Shoucheng Holdings (00697) repurchased 16.05 million shares for 36.3578 million, with a year-to-date total of 90.146 million shares, representing 1.237% of its total share capital [2]. Group 2: Other Notable Buybacks - Vitasoy International (00345) repurchased 1.3980 million shares for 11.3964 million, with a year-to-date total of 4.25 million shares, representing 0.405% of its total share capital [2]. - IGG (00799) repurchased 150,000 shares for 6.145 million, with a year-to-date total of 17.809 million shares, representing 1.527% of its total share capital [3]. - China Hongqiao (01378) repurchased 300,000 shares for 7.594 million, with a year-to-date total of 154 million shares, representing 1.650% of its total share capital [2].

康宁杰瑞制药-B(09966)发布公告，于2025年10月14日斥资396.69万港元回购29.3万股。 ...

智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2025年10月14日斥资396.69万港元回购29.3万 股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年10月14日 若購回/贖回股份將於期終結存日期之後購回/贖回結算完成之時予以註銷，則該等購回/贖回股份仍屬A部所述期終結存當日的已發行股份的一部分。該等購回/贖回股份的詳情應在B部作 出披露。 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 ...

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) announced a share buyback on October 13, 2023, spending HKD 1.486 million to repurchase 108,000 shares [1] Summary by Category Company Actions - The company executed a buyback of 108,000 shares at a total cost of HKD 1.486 million on October 13, 2023 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 有關2024年度報告的補充公告 茲提述康寧傑瑞生物製藥（「本公司」）日期為2025年4月28日的截至2024年12月 31日止年度的年度報告（「2024年度報告」）。除另有界定者外，本公告所用詞彙與 2024年度報告所載列者具有相同涵義。 本公司董事（「董事」）會（「董事會」）謹此提供以下有關其庫存股份、全球發售及 先舊後新配售所得款項用途以及首次公開發售後股份獎勵計劃的補充資料。 1. 庫存股份 本公司尚未確定庫存股份的擬定用途，並將依市場狀況及自身資本管理需 要，遵照《上市規則》的規定動用庫存股份。 2. 全球發售及先舊後新配售所得款項用途 下表載列於報告期間初期結轉的全球發售及先舊後新配售所得款項淨額明 細： 百萬港元 百分比 關鍵藥物開發項目 KN046的研發及商業化 • 正在進行和計 ...